Heidelberg Pharma AG

Business and Financial Review • May 21, 2014

News Details

Ad-hoc | 21 May 2014 12:48

WILEX AG: WILEX returns rights from collaboration in oncology to UCB and UCB waives repayment of the shareholder loan

WILEX AG / Key word(s): Agreement

21.05.2014 12:48

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX returns rights from collaboration in oncology to UCB and UCB waives
repayment of the shareholder loan

Munich, Germany, 21 May 2014. WILEX AG (ISIN DE0006614720 / WL6 / FSE)
today announced that due to the strategic re-alignment implemented at WILEX
AG, the collaboration agreement for the clinical product candidates WX-554
and WX-037 and for three preclinical antibody programmes has been
terminated by mutual agreement. WILEX will return all rights granted and
will transfer all intellectual property, data and documents generated in
connection with the programmes to UCB. Furthermore an agreement regarding
an antibody programme for non-oncology indications signed last year has
been terminated.

WILEX will receive a final payment for reimbursement of R&D expenses. UCB
has agreed to waive repayment of the EUR 2.5 million shareholder loan
granted in December 2010 on completion of the transfer. This does not
affect UCB's role as a shareholder of WILEX AG.

---

Information and Explaination of the Issuer to this News:

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates based on antibodies and small molecules, which are available for
out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and an antibody drug conjugate (ADC) technology
platform. Our customers and partners include leading international
pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange:
ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available
at www.wilex.com

Contact IR/PR support
WILEX AG MC Services AG
Corporate Communications Katja Arnold (CIRO)
Sylvia Wimmer Tel.: +49 (0)89-210 228-40
Tel.: +49 (0)89-41 31 38-29 Mobile: +49 (0)160 9360 3022
Email: investors[at]wilex.com Email: katja.arnold[at]mc-services.eu
Grillparzerstr. 10, 81675 Munich

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

21.05.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---